


www.adipogen.com

TNF Ligands Multimeric Proteins *Higher Activity – Lower Endotoxin*

AdipoGen® Multimeric Proteins are high activity constructs in which two trimeric TNFSF ligands are linked via the oligomeric collagen domain of ACRP30 [ACRP30*headless*] and therefore mimic the membrane-bound forms of the proteins.



Endogenous TNF superfamily ligands are either active as membrane-form (e.g. FasL, TRAIL, CD40L, OX40L) or are secreted and activated through oligomerization by the binding of proteoglycans at the surface of cells (e.g. APRIL).

To mimic endogenous TNF ligands activity, the oligomerization of recombinant TNF ligands can be triggered:

- by fusing the TNF superfamily ligands, soluble form, to the collagen domain of the protein ACRP30 (which itself has no functional activity) to form a hexameric structure and therefore creating "Multimeric Proteins", or
- by adding a cross-linking antibody called "TNF Ligands Enhancer" (Prod. No. AG-35B-0001).

Multimeric FasL[™] [*Mega*FasL[™]]

FasL (human) (multimeric) (rec.)

AG-40B-0130

10 µg | 3 x 10 µg

MultimericFasL[™] very effectively simulates the natural membrane-assisted aggregation of FasL *in vivo*.

Source:	HEK 293 cells.
Sequence:	Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30 <i>headless</i> (aa 18-111) and a FLAG®-tag.
Specificity:	Binds to human and mouse Fas.
Biological Activity:	Induces apoptosis of human Jurkat T cells at a concentration of <1ng/ml.
Endotoxin Content:	<0.01 EU/µg purified protein (LAL test; Lonza).

LITERATURE REFERENCES: Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. **23**, 1428 (2003) • A Fas agonist induces high levels of apoptosis in haematological malignancies: P. Greaney, et al.; Leuk. Res. **30**, 415 (2006)




FIGURE: Oligomerisation of FasL (human) efficiently triggers Jurkat cell death.

METHOD: Jurkat cells were treated 0/N with the indicated concentrations of FasL (human) (multimeric) (rec.) (AG-40B-0130), Fc (human):FasL (human) (rec.) (AG-40B-0132), FasL (human) (rec.) (AG-40B-0001) or FasL (human) (rec.) + Enhancer (AG-44B-0001) (2 fold-dilutions, first concentration of 1000ng/ml). Cell death was quantified using PMS/MTS. The oligomeric FasL recombinant proteins (FasL (human) (multimeric), Fc (human):FasL (human) and FasL (human) + Enhancer) kill Jurkat cells at IC₅₀ <0.2ng/ml.

See Backcover for more Products!

The Largest Panel of <u>Ultrapotent *Multimeric*Ligands</u>[™]! Equivalent to *Mega*Ligands – www.megaligands.com

MultiPacks for additional big savings!

• Bulk Quantities for in vivo cancer immunotherapy and vaccination studies in mice!

FIGURE: CD40L (human) (mu does not need an enhancer to 6-40B-0020	timeric) (rec.) (Prod. No. AG-40B-00
별 照 크 뉴 러 팩 플 FIGURE: CD40L (human) (mu does not need an enhancer to 5-40B-0020	CD40L(h) + enhancer
별 照 크 뉴 러 팩 플 FIGURE: CD40L (human) (mu does not need an enhancer to 5-40B-0020	timeric) (rec.) (Prod. No. AG-40B-00 induce B cells activation.
	10 µg 3 x 10 µ
G-40B-0107	
	10 µg 3 x 10 µ
i-40B-0088 i-40B-0089 i-40B-0035	10 μg 3 x 10 μ 10 μg 3 x 10 μ 10 μg 3 x 10 μ
. 400 0000	10
1-40B-0029	10 µ
-40B-0019	10 µg 3 x 10 µ
i-40B-0019 i-40B-0021	
	10 μg 3 x 10 μ 10 μg 3 x 10 μ
	i-40B-0089

www.adipogen.com

L

info@adipogen.com

For local distributors please visit our website.